TS-068290 — The Need Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require invasive procedures and may not detect exposure at lower dose ranges. …

TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…

TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-062320 — The Need: Addressing Susceptibility to Cutaneous Leishmaniasis Cutaneous leishmaniasis, caused by the intracellular parasite Leishmania major and transmitted by sand flies, poses a significant threat to susceptible populations. This disfiguring disease results in large skin lesions, impacting both …

TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.

TS-038221 — A knock-in murine model that expresses high levels of GFP in CXCR3 positive cells.

TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.

TS-030264 — A chemical process to produce ceratamine A and B.

TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.